At today's price, Merck's stock is pricing in about 12.0% annual free-cash-flow growth for the next ten years — roughly 30% faster than its actual 5-year FCF growth (9.3% a year), a pace the market expects Merck to sustain right through Keytruda's 2028 U.S. patent expiration.
At its current price, MRK implies ~12.0% annual FCF growth for the next 10 years, discounted at 9%.
Merck's actual FCF growth has averaged 9.3% a year over the past 5 years; revenue grew just 7.5% a year over the same span.
Required growth vs. historical growth
Required growth from the reverse DCF below. Historical CAGRs from 10-K FY2021-FY2025 (FCF and revenue figures).
Sensitivity: what if the discount rate moves?
| WACC | Required growth | Note |
|---|---|---|
| 8% | 9.6% | Nearly matches the 5-yr FCF pace (9.3%) |
| 9% (base case) | 12.0% | Typical large-cap stable-dividend assumption |
| 10% | 14.3% | Clearly above historical pace |
| 12% | 18.3% | Well above historical pace |
At 8%, the required rate (9.6%) is almost identical to Merck's actual 5-year FCF pace — a reasonable ask. Raise the discount rate to just 10%, though, and the gap widens clearly beyond what recent history supports.
What would move this number
- Using the 3-year average FCF ($13.20B) instead of FY2025's figure ($12.36B) as the base lowers the required growth rate to about 10.7% at a 9% discount rate, since 2025's FCF ran 6% below that average.
- Treating the October 2025 Verona Pharma acquisition's debt-funded impact on net debt as a one-time event and excluding it would modestly lower the required growth rate.
- Lowering the terminal growth rate from 2.5% to 2.0% would modestly raise the required 10-year growth rate, since more of the total value would then need to come from the explicit growth period rather than the terminal value.
Show your work
Inputs, sources, model assumptions, and the calculation
- Share price$148.35 — stockanalysis.com, Aug 28, 2026 close
- Market cap$366.0B
- Total debt$49.34B — 10-K FY2025 balance sheet (current portion $2.59B + long-term $46.75B)
- Cash and equivalents$14.57B — 10-K FY2025 balance sheet
- Net debt$34.77B — calculated
- Base FCF (FY2025)$12.36B — 10-K FY2025 cash flow statement: $16.47B operating cash flow minus $4.11B capex
- Discount rate (WACC)9% base case (8%/10%/12% tested)
- Terminal growth rate2.5% — long-run GDP-level assumption
Normalization check: 3-year average FCF (2023-2025) is $13.20B; FY2025's figure ($12.36B) is -6.4% below that average — within the ±40% threshold, so used as-is without adjustment.
Model: free cash flow is assumed to grow at a constant annual rate g for 10 years, then at a 2.5% terminal rate thereafter, solved by bisection for the value of g that equates present value to today's target enterprise value (market cap plus net debt, $400.77B).
Historical CAGR check: 5-yr FCF CAGR = ($12.36B ÷ $8.674B)^(1/4) − 1 = 9.3%. 5-yr revenue CAGR = ($65.011B ÷ $48.704B)^(1/4) − 1 = 7.5%. Most recent 1-year revenue growth (2024→2025) = 1.3%.
The fine print
- This isn't a fair-value price target — it only shows what the current price already assumes.
- Change the discount rate or the FCF base, and the answer moves — see the sensitivity table above.
- Whether 12.0% growth is realistic depends heavily on how Merck manages the 2028 Keytruda patent cliff and Gardasil's international recovery — not on this math alone.
- A reverse DCF shows what the market currently expects — it does not say what the stock is "worth."
- Any investment decision, and its outcome, is your own responsibility.
Frequently asked questions
What growth rate does MRK's stock price assume?
At today's price, Merck's stock is pricing in about 12.0% annual free-cash-flow growth for the next ten years, at a 9% discount rate.
How does that compare to Merck's actual growth?
Merck's actual 5-year FCF CAGR (2021-2025) was 9.3% a year, and its 5-year revenue CAGR was 7.5% — both below the 12.0% the current price requires. Revenue grew just 1.3% in the most recent year alone.
What share price was used for this analysis?
This analysis used $148.35, as of the Aug 28, 2026 close.